Joint Letter on COVID-19 and Cancer
The Cancer Drug Development Forum fully supports the European Cancer Patient Coalition's initiative, Joint Letter on COVID-19 and Cancer, and calls for the action to identify the impact of the pandemic on cancer services and design services to mitigate this. CLICK...
CDDF 12th Spring Conference meeting report is now available!
The CDDF 12th Spring Conference took place on 8-10 February 2021, virtually. This multi-stakeholder, interactive meeting offered plenary lectures with moderated discussions, including case studies as well as networking opportunities. The programme focused on the...
NEW CDDF INDUSTRY PARTNER – Varian Medical Systems
Varian Medical Systems becomes first medical technology company to join The Cancer Drug Development Forum (CDDF). We welcome Varian to the CDDF Industry Partners Platform and look forward to great collaboration in 2021! To read...
HAPPY HOLIDAY SEASON!
Unlocking the Value of Personalised Cancer Care
Access to Personalised Oncology in Europe, a new report by LSE consulting commissioned by EFPIA, identifies the barriers to better deployment of personalised cancer treatment for European cancer patients and makes concrete recommendations on how to advance and...
Virtual Meeting: Together against Cancer: How can Europe benefit from breakthroughs in personalised oncology?
A virtual meeting, "How can Europe benefit from breakthroughs in personalised oncology?" is organized by the European Federation of Pharmaceutical Industries and Associations, the London School of Economics (LSE), the European Cancer Patient Coalition (ECPC), and the...
CDDF Spring Conference 2021 will go virtual!
We were looking forward to seeing everyone at the Spring Conference 2021 in Noordwijk. However, due to the continuing threat of the COVID-19 pandemic and its impact on our ability to travel, after thoughtful discussions, the Cancer Drug Development Forum has decided...
A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?
Cancerworld published an article, "A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?" on 28 October 2020. To read the full article and Prof. Jaap Verweij's comment, click the following link:...
Oncology Meeting: EORTC – IBCD 2020 (23 October 2020)
IBCD 2020 will explore routes through the continually evolving scientific, methodological and regulatory environment for drug and biomarker development. The EORTC, NCI, EMA, and AACR will will work alongside FDA and PMDA specialists to build upon recommendations and...